title: [Adoptive immunotherapy with interleukin 2. Initial results of a pilot study in 6 cancer patients].
abstract: Adoptive immunotherapy of cancer consists of using interleukin-2 to induce the formation of lymphokine-activated killer (LAK) cells which are toxic to tumoral cells. Six patients, 3 with hypernephroma and 3 with melanoma, were treated with interleukin-2. Drug toxicity consisted of capillary leakage syndrome in one case and reversible renal impairment in another. One patient showed an objective response; transient subjective improvement was observed in all patients.
authors.affiliation: Service de Médecine, Institut Jules Bordet, Université libre de Bruxelles, Belgique.
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
authors.forename: D
authors.initials: D
authors.lastname: Bron
authors.forename: A
authors.initials: A
authors.lastname: Delforge
authors.forename: J J
authors.initials: JJ
authors.lastname: Body
authors.forename: N
authors.initials: N
authors.lastname: Verboven
authors.forename: J
authors.initials: J
authors.lastname: Frühling
authors.forename: P
authors.initials: P
authors.lastname: Stryckmans
authors.forename: J
authors.initials: J
authors.lastname: Klastersky
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D000368:Aged; D002199:Capillary Permeability / Q000187:drug effects; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D007694:Killer Cells, Natural; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged
chemical_list: D007376:Interleukin-2
vernacular_title: Immunothérapie adoptive par interleukine-2. Premiers résultats d'une étude pilote chez 6 malades cancéreux.